RoboSense Wins CES 2020 Innovation Award for Autonomous Vehicle Technology
8.11.2019 12:19:00 EET | Business Wire | Press release
RoboSense http://www.robosense.ai, the world’s leading autonomous driving LiDAR perception solution provider, announced today that it has won the CES 2020 Innovation Award the second year in a row for autonomous vehicle technology. RoboSense won this year’s CES 2020 Innovation Award for the first MEMS-based Smart LiDAR Sensor, the RoboSense RS-LiDAR-M1, winning in the Vehicle Intelligence and Self-Driving Technology category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191108005194/en/
RoboSense RS-LiDAR-M1 (Graphic: Business Wire)
The RoboSense award-winning RS-LiDAR-M1 is the world’s first and only MEMS-based smart LiDAR sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC(System on a Chip). The RS-LiDAR-M1 goes beyond traditional LiDAR, providing full data collection and comprehension. As a ground-breaking product, the RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but also processes road data in real-time, with a built-in AI algorithm and SoC, while at the same time synchronizing high-precision positioning output; road traffic signage; lane markings, driving areas, road curbs, and obstacle detection; tracking; and classification. Also, it is the world’s smallest MEMS-based solid-state LiDAR, providing a low cost, high stability, and superior manufacturability to meet automotive-grade and serial production requirements.
“Driving Safety is the most critical challenge for the Autonomous driving vehicles. Perception is the first sense for the AD vehicles to precept the surrounding environment. To ensure a completely safe perception working in all conditions, LiDAR with smart perception algorithm and supporting functions are indispensable. We are very proud that our smart LiDR sensor concept have been recognized by the customers and different application users, ” said Dr. Leilei Shinohara, RoboSense Vice President of R&D.
The RoboSenseRS-LiDAR-M1 Smart LiDAR Sensor will be on display in the Innovation Awards Showcaseat the upcoming CES 2020. The complete list of CES 2020 Innovation Honorees, including product descriptions and photos, can be found at CES.tech/Innovation. RoboSense will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About CES & CES Innovation Awards
An annual program that celebrates outstanding design, the CES Innovation Awards recognizes the best technology products of the year. The CES Innovation Awards are sponsored by the Consumer Technology Association (CTA)™, owner and producer of CES, the world’s largest and most influential technology event.
CES 2020 will showcase life-changing technology across every major industry. CES provides access to the very latest transformative tech, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports tech, machine learning and more. For the latest news and show announcements, visit CES.tech. Follow CES online at CES.tech and on social.
About RoboSense
Founded in 2014, RoboSense is the world’s leading provider of LiDAR environment perception solutions designed to provide a higher performance, safer, more reliable, and lower cost LiDAR system for autonomous vehicles. RoboSense has entered into strategic partnerships with many top car companies, tier one manufacturers and technology companies with a global reach. For more information about RoboSense, visit: https://www.robosense.ai
Photos:
CES 2020 Innovation Award Honoree Logo: http://www.thomas-pr.com/136/photos/robosenseces2020innovationawardlogo.html
RS-LiDAR-M1 Smart LiDAR Sensor: http://www.thomas-pr.com/136/photos/robosensem1lidar.html
RoboSense Logo: http://www.thomas-pr.com/136/photos/robosenselogo.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005194/en/
Contact information
Press:
Karen Thomas/Eva Yutani
Emails: kthomas@thomaspr.com / eyutani@thomaspr.com
(631) 549-7575 website: http://www.thomaspr.com
Company:
Cassie Gong, Overseas PR Manager
Email: sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 20266.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6.5.2026 13:25:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirteen newly hired non-executive employees. The equity awards were granted on May 1, 2026 and consisted of options to purchase an aggregate of 125,335 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 59,625 shares. The options have an exercise price per share equal to $9.01, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
AB InBev Wins Cannes Lions Creative Marketer of the Year for an Unprecedented Third Time6.5.2026 13:03:00 EEST | Press release
The Cannes Lions International Festival of Creativity has announced AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) as the 2026 Creative Marketer of the Year. The honorary accolade is presented to a marketer that has amassed a body of iconic, Lion-winning work over a sustained period of time. AB InBev’s continued commitment to using creativity as a growth lever across its portfolio resulted in it winning an impressive 37 Lions at last year’s Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506536538/en/ AB InBev is the first company in Cannes Lions’ history to be honoured with the award for a third time. Since 2021 the global brewer has embarked on a journey of inorganic to organic growth, betting on creativity as a key competitive advantage that has contributed to strong performance and increased revenues. About the honour, Simon Cook, CEO, LIONS, said: “AB InBev has embedded creativity into how it operates
Aircall Acquires Vogent to Advance Its AI Voice Agent Built Natively into Business Phones6.5.2026 13:03:00 EEST | Press release
Aircall, the AI-powered customer communications platform trusted by more than 22,000 businesses worldwide, today announced the acquisition of Vogent, an AI voice agent company. The acquisition adds a new layer of specialized voice AI technology to Aircall’s platform – strengthening the technology behind Aircall’s AI Voice Agent and moving it from already great to best-in-class. While AI agents' chat or email based communication channels have exploded in popularity, voice is its own discipline – with unique demands around timing, interruption handling, call flows, and production reliability. Voice channel also comes with the highest expectations from customers, further putting scrutiny around the readiness of the technology. For many businesses deploying AI voice agents, the experience has not lived up to the hype. With Vogent, Aircall enhances its AI Voice Agents with a deeper set of specialized AI technologies, including advanced speech models, more reliable turn-taking, and higher pr
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates6.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now clear. BRUKINSA has firmly established itself as the foundational, best-in-class BTK inhibitor with unmatched long-term efficacy and safety data for the treatment of CLL and as the only BTKi with proven efficacy superiority over ibrutinib which has resulted in clear global revenue leadership. The fixed-duration combination of sonrotoclax, a foundational, next-generation BCL2 inhibitor,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom